Cost Effectiveness of Tissue Plasminogen Activator

Publisher Website
Google Scholar
Abstract
Not so long ago, therapies that led to a survival advantage in randomized trials were quickly endorsed and adopted. The costs required to achieve the clinical benefit were of only minimal interest to the primary decision makers — physicians seeking the best outcomes for their patients. And in that era there would have been little controversy over whether tissue plasminogen activator (t-PA) is a more effective thrombolytic agent than intravenous streptokinase. Laboratory and clinical studies show that t-PA opens coronary arteries occluded by thrombus more rapidly than streptokinase,1 and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded . . .